EP2102208B1 - Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen - Google Patents

Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen Download PDF

Info

Publication number
EP2102208B1
EP2102208B1 EP07847809.6A EP07847809A EP2102208B1 EP 2102208 B1 EP2102208 B1 EP 2102208B1 EP 07847809 A EP07847809 A EP 07847809A EP 2102208 B1 EP2102208 B1 EP 2102208B1
Authority
EP
European Patent Office
Prior art keywords
group
compound according
compound
equal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07847809.6A
Other languages
English (en)
French (fr)
Other versions
EP2102208A1 (de
Inventor
José Ignacio Andrés-Gil
Manuel Jesús Alcázar-Vaca
Frank Matthias Dautzenberg
Joannes Theodorus Maria Linders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to EP07847809.6A priority Critical patent/EP2102208B1/de
Publication of EP2102208A1 publication Critical patent/EP2102208A1/de
Application granted granted Critical
Publication of EP2102208B1 publication Critical patent/EP2102208B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Definitions

  • the present invention concerns aryl and heteroaryl substituted diaza-spiro- pyridinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity. It further relates to their preparation, compositions comprising them and their use as a medicine.
  • MCH melanin-concentrating hormone
  • MCH Melanin concentrating hormone
  • CNS central nervous system
  • MCH-1 receptor was considered a valuable target for the treatment of obesity as MCH promotes feeding behaviour in rodents ( Nature (1996), 380, 243-247 ). Recently however, it was shown that MCH-1 antagonism produces anxiolytic and antidepressant profiles in rodents ( Nat. Med. (2002) 8, 825-830 ; Neuropharmacology (2004), 46, 457-467 ; Neuropsychopharmacology (2006), 31(1), 112-120 ; Neuropsychopharmacology (2006), 31(6), 1135-1145 ). Thus, it is currently generally accepted that MCH receptors, particularly the MCH-1 receptor, are a good target for the treatment of affective spectrum disorders ( Eur. J. Neuroscience (2000) 12, 1194-1216 ).
  • MCH-1 receptor mRNA and protein are distributed in various hypothalamic nuclei including the paraventricular nucleus and several limbic structures all implicated in the regulation of emotion and stress ( Eur. J. Neuroscience (2000) 12, 1194-1216 ). In addition, dense labelling is detected in the nucleus accumbens shell ( J. Comp. Neurol. (2001) 435, 26-40 ). Injection of MCH directly into the paraventricular nucleus has been found to increase plasma adrenocorticotropic hormone (ACTH) and to alter sleep architecture ( Verret et al. 2003, BMC Neurosci 4:19 ).
  • ACTH plasma adrenocorticotropic hormone
  • MCH corticotrophin-releasing factor
  • CRF corticotrophin-releasing factor
  • MCH-1 antagonists A large number of companies is now actively pursuing the development of MCH-1 antagonists and a wide range of structural types have been reported in a number of patent publications, mostly in relation to the regulation of food intake and energy expenditure ( Expert Opin. Ther. Patents (2005) 15(10 )). The majority of reported MCH-antagonists incorporate a basic centre and two (hetero)aromatic parts, joined by linkers.
  • WO 2005/085200 (Banyu Pharmaceutical Co., Ltd) discloses pyridinone, pyrimidinone and pyridazinone-derivatives for use as MCH-1 antagonists.
  • WO 2003/033480 discloses different bicyclic heterocycles, such as thienopyrimid-4-one-, benzopyrimid-4-one- and phtalimide-derivatives, for use as MCH-1 antagonists.
  • WO 2003/097047 and WO 2005/040157 (Eli Lilly and Company) and WO 2005/070925 (Aventis Pharma GmbH) report different aromatic 5-membered ring heterocycles, such as oxazole- and oxadiazole-derivatives, for use as MCH-1 antagonists.
  • WO 2004/011438 and WO 2005/070898 (Aventis Pharma Deutschland GMBH) disclose diaryl-substituted cyclic urea derivatives as MCH-1 antagonist.
  • MCH melanin-concentrating
  • the compounds according to the invention exhibit very low or no hERG-channel interactions, which interactions are undesirable, but widely associated with the compounds of the prior art.
  • the compounds of the invention are preferred over the prior art compounds for their substantial lack of hERG-channel interactions and their absence of QT-prolongation.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a therapeutically effective amount of a compound according to the invention, in particular a compound according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof, or a quaternary ammonium salt thereof.
  • the invention also relates to a method for preventing and/or treating a disorder or disease responsive to antagonism of the MCH receptor, in particular to antagonism of the MCH-1 receptor in an individual in need thereof comprising the step of administering to said individual a compound or a pharmaceutical composition according to the present invention.
  • said disorder or disease is selected from the group comprising psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders; and neurological disorders.
  • the invention also relates to the use of a compound according to the invention as a medicament and for the preparation of a medicament for the prevention and/or treatment of a disorder or disease responsive to antagonism of the MCH receptor, in particular to antagonism of the MCH-1 receptor.
  • the invention relates to the use of a compound according to the invention for the preparation of a medicament for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders.
  • the compound can be used for treating obesity, diabetes, sexual disorders and neurological disorders.
  • a compound according to the invention, in particular according to Formula (I), may also be suitable as add-on treatment or combination treatment and/or prophylaxis in the above listed diseases, in particular for the prevention and/or treatment of psychiatric disorders, in combination with antidepressants, anxiolytics and/or antipsychotics which are currently available or in development or which will become available in the future, in particular to improve efficacy and/or onset of action.
  • antidepressants anxiolytics and/or antipsychotics
  • antipsychotics which are currently available or in development or which will become available in the future, in particular to improve efficacy and/or onset of action.
  • antidepressants anxiolytics and/or antipsychotics
  • compounds are evaluated in combination with antidepressants, anxiolytics and/or antipsychotics for attenuation of stress-induced hyperthermia.
  • the invention therefore also relates to the use of the compounds according to the invention in combination with one or more other compounds selected from the group of antidepressants, anxiolytics and antipsychotics, to a pharmaceutical composition comprising the compounds according to the invention and one or more other compounds selected from the group of antidepressants, anxiolytics and antipsychotics, as well as to a process for the preparation of such pharmaceutical compositions.
  • the invention also relates to the use of the compounds according to the invention in combination with one or more other compounds selected from the group of lipid-lowering compounds for the prevention and/or treatment of obesity, to a pharmaceutical composition comprising the compounds according to the invention and one or more other compounds selected from the group of lipid-lowering compounds, as well as to a process for the preparation of such pharmaceutical compositions.
  • the invention relates to a compound according to the invention, wherein k, 1, m, n are each independently from each other, an integer equal to 1, 2, or 3, with the provision that (k+1) and (m+n) is equal to 2, 3, or 4.
  • the invention relates to a compound according to the invention, wherein A is selected from the group of radicals (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8), (b-9), (b-10), (c-1), (c-2), (c-3), (c-4), (c-5), (c-6), (c-7), (c-8), (d-1), (d-2), (d-3), (d-4), (d-5), (d-6), (e-1), (e-2), (e-3), (e-4), (e-5), (e-6), (f-1), (f-2), (f-3), and (f-4), as depicted below, wherein one of the -CH 2 -moieties may be replaced by O ; and wherein each of the -CH 2 - moieties may be substituted with oxo.
  • radicals may be incorporated into Formula (I) from the right to the left or from the left to the right, i.e. each end of the radical may be attached to either the radical R 3 or the aryl/heteroaryl-radical in Formula (I).
  • the invention relates to a compound according to the invention, wherein A is selected from the group of (a-1), (b-1), (b-3), (b-5), and (c-2).
  • A is a radical according to Formula (cc-2), as depicted below.
  • A is a radical according to (aa-1) or (bb-1), as depicted below.
  • the invention relates to a compound according to the invention, wherein R 3 is selected from the group of hydrogen, C 36 cycloalkyl and C 1-5 alkyl, in particular from the group of hydrogen C 35 cycloalkyl and C 1-3 alkyl, in particular from the group of hydrogen, methyl, ethyl, propyl and cyclopropyl.
  • the invention relates to a compound according to the invention, wherein X is carbon-H or nitrogen.
  • the invention relates to a compound according to the invention, wherein each of R 4 and R 5 , independently from each other, are selected from the group of hydrogen, halo, C 1-3 alkyl, and C 1-3 alkyloxy.
  • the invention relates to a compound according to the invention, wherein p is zero or 1.
  • the invention relates to a compound according to the invention, wherein q is zero.
  • the invention relates to a compound according to the invention, wherein Y 1 and Y 3 are each, independently from each other, selected from the group of a single bond and O.
  • the invention relates to a compound according to the invention, wherein B is selected from the group of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; in particular from the group of phenyl, pyridinyl and pyridazinyl ; in particular is B phenyl.
  • the invention relates to a compound according to the invention, wherein B is substituted with one halo substituent, in particular fluoro or halo.
  • the invention relates to a compound according to the invention, wherein the moiety B-Y 1 -Y 2 -Y 3 is selected from the radicals (a1-1) to (d1-5) as listed below, optionally substituted with r substituents R 6 , each independently from each other, selected from the group of halo, cyano, hydroxy, amino, oxo, carboxyl, nitro, thio, formyl, C 1-3 alkyl, and C 1-3 alkyloxy ; and wherein r is an integer, equal to 1 or 2 ; or two substituents R 6 may be combined into a radical -CH 2 CH 2 CH 2 - or -OCH 2 O-.
  • the moiety B-Y 1 -Y 2 -Y 3 is selected from the radicals (a1-2), (al-3) and (al-5), optionally substituted with r substituents R 6 , each independently from each other, selected from the group of halo, cyano, hydroxy, amino, oxo, carboxyl, nitro, thio, formyl, C 1-3 alkyl, and C 1-3 alkyloxy ; and wherein r is an integer, equal to 1 or 2 ; or two substituents R 6 may be combined into a radical -CH 2 CH 2 CH 2 - or -OCH 2 O-.
  • the invention relates to a compound according to the invention, wherein one or more, in combination or alone, of the following restrictions apply :
  • the invention relates to a compound according to the invention, wherein A is selected from the group of (a-1), (b-1), (b-3), (b-5), and (c-2),
  • the invention relates to a compound according to the invention, wherein A is selected from the group of (a-1), (b-1), (b-3), (b-5), and (c-2),
  • the invention relates to a compound according to the invention, wherein A is selected from the group of (a-1), or (b-1);
  • alkyl is a straight or branched saturated hydrocarbon radical having the indicated number of carbon atoms, i.e. when C 1-3 alkyl is indicated, the alkyl radical may contain from 1 to 3 carbon atom; or when C 1-5 alkyl is indicated, the alkyl radical may contain from 1 to 5 carbon atom.
  • Each radical may optionally be substituted on one or more carbon atoms with one or more substituents selected from the group of halo, cyano, hydroxy, amino, oxo, carboxyl, nitro, thio, and formyl.
  • alkyl is methyl, ethyl, propyl or isopropyl.
  • Further radicals that are embraced within the scope are e.g. hydroxymethyl, 1-hydroxyethyl, 1-hydroxypropyl, fluoromethyl, difluoromethyl and trifluoromethyl.
  • C 3-6 cycloalkyl as a group or part of a group defines cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • C 3-6 cycloalkyl may optionally be substituted on one or more carbon atoms with one or more substituents selected from the group of halo, cyano, hydroxy, amino, oxo, carboxyl, nitro, thio, and formyl.
  • aryl is naphthyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, cyano, hydroxy, amino, oxo, carboxyl, nitro, thio, formyl, and C 1-3 alkyloxy.
  • halo is a substituent selected from the group of fluoro, chloro, bromo, and iodo.
  • halo is fluoro, chloro or bromo.
  • a bond can be any bond, including a covalent bond, a single bond, a double bond, a triple bond, a coordination bond and a hydrogen bond.
  • a pharmaceutically acceptable acid addition salt is defined to comprise a therapeutically active non-toxic acid addition salt form that a compound according to Formula (I) is able to form.
  • Said salt can be obtained by treating the base form of a compound according to Formula (I) with an appropriate acid, for example an inorganic acid, for example hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid and phosphoric acid ; an organic acid, for example acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicylic acid, p-aminosalicylic acid and pamoic acid.
  • said acid addition salt form may be converted into the free base form by treatment with an appropriate base.
  • the compound according to Formula (I) containing an acidic proton may also be converted into a therapeutically active non-toxic metal or amine addition salt form (base addition salt) by treatment with an appropriate organic and inorganic base.
  • base salt forms comprise, for example, the ammonium salts, the alkaline and earth alkaline metal salts, in particular lithium, sodium, potassium, magnesium and calcium salts, salts with organic bases, e.g. the benzathine, N -methyl-D-glucamine, hybramine salts, and salts with amino acids, for example arginine and lysine.
  • said salt form can be converted into the free form by treatment with an appropriate acid.
  • addition salt as used in the framework of this application also comprises a solvate that the compound according to Formula (I), as well as a salt thereof, is able to form.
  • solvates are, for example, hydrates and alcoholates.
  • the N -oxide form of the compound according to Formula (I) is meant to comprise a compound of Formula (I) wherein one or several nitrogen atoms are oxidized to so-called N -oxides, particularly those N -oxides wherein one or more tertiary nitrogens (e.g. of the piperazinyl or piperidinyl radical) are N -oxidized.
  • N -oxides can easily be obtained by a skilled person without any inventive skills and they are obvious alternatives for a compound according to Formula (I) since these compounds are metabolites, which are formed by oxidation in the human body upon uptake.
  • oxidation is normally the first step involved in drug metabolism ( Textbook of Organic Medicinal and Pharmaceutical Chemistry, 1977, pages 70- 75 ).
  • the metabolite form of a compound can also be administered to a human instead of the compound per se, with much the same effects.
  • a compound of Formula (I) may be converted to the corresponding N -oxide form following art-known procedures for converting a trivalent nitrogen into its N -oxide form.
  • Said N -oxidation reaction may generally be carried out by reacting the compound of Formula (I) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g.
  • 3-chlorobenzenecarboperoxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert -butyl hydroperoxide.
  • Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • a quaternary ammonium salt of compound according to Formula (I) defines said compound which is able to form by a reaction between a basic nitrogen of a compound according to Formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, in particular methyliodide and benzyliodide.
  • an appropriate quaternizing agent such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, in particular methyliodide and benzyliodide.
  • Other reactants with good leaving groups may also be used, such as, for example, alkyl trifluoromethanesulfonates, alkyl methanesulfonates and alkyl p-toluenesulfonates.
  • a quaternary ammonium salt has at least one positively charged nitrogen.
  • Pharmaceutically acceptable counterions include
  • the invention also comprises a derivative compound (usually called "pro-drug") of a pharmacologically-active compound according to the invention, in particular according to Formula (I), which is degraded in vivo to yield a compound according to the invention.
  • Pro-drugs are usually (but not always) of lower potency at the target receptor than the compounds to which they are degraded.
  • Pro-drugs are particularly useful when the desired compound has chemical or physical properties that make its administration difficult or inefficient. For example, the desired compound may be only poorly soluble, it may be poorly transported across the mucosal epithelium, or it may have an undesirably short plasma half-life. Further discussion on pro-drugs may be found in Stella, V. J. et al., "Prodrugs", Drug Delivery Systems, 1985, pp. 112-176 , and Drugs, 1985, 29, pp. 455-473 .
  • a pro-drug form of a pharmacologically-active compound according to the invention will generally be a compound according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N -oxide form thereof, or a quaternary ammonium salt thereof, having an acid group which is esterified or amidated. Included in such esterified acid groups are groups of the formula -COOR x , where R x is a C 1-6 alkyl, phenyl, benzyl or one of the following groups :
  • Amidated groups include groups of the formula - CONR y R z , wherein R y is H, C 1-6 alkyl, phenyl or benzyl and R z is -OH, H, C 1-6 alkyl, phenyl or benzyl.
  • a compound according to the invention having an amino group may be derivatised with a ketone or an aldehyde such as formaldehyde to form a Mannich base. This base will hydrolyze with first order kinetics in aqueous solution.
  • stereochemically isomeric form defines all the possible stereochemically isomeric forms that a compound of Formula (I) may possess.
  • chemical designation of a compound denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration.
  • Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Hence, all stereochemically isomeric forms of a compound of Formula (I) are intended to be embraced within the scope of this invention.
  • an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center.
  • the configuration of the second stereogenic center is indicated using relative descriptors [ R *, R *] or [ R *, S *], where R * is always specified as the reference center and [ R *, R *] indicates centers with the same chirality and [ R *, S *] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an S configuration and the second center is R , the stereo descriptor would be specified as S -[ R *, S *].
  • the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number is arbitrarily always in the " ⁇ " position of the mean plane determined by the ring system.
  • the position of the highest priority substituent on the other asymmetric carbon atom in the ring system (hydrogen atom in a compound according to Formula (I)) relative to the position of the highest priority substituent on the reference atom is denominated " ⁇ ", if it is on the same side of the mean plane determined by the ring system, or " ⁇ ", if it is on the other side of the mean plane determined by the ring system.
  • a compound according to the invention is inherently intended to comprise all isotopic combinations of its chemical elements.
  • a chemical element in particular when mentioned in relation to a compound according to Formula (I), comprises all isotopes and isotopic mixtures of this element, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form.
  • a compound according to the invention therefore inherently comprises a compound with one or more isotopes of one or more element, and mixtures thereof, including a radioactive compound, also called radiolabelled compound, wherein one or more non-radioactive atoms has been replaced by one of its radioactive isotopes.
  • radiolabelled compound is meant any compound according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N -oxide form thereof, or a quaternary ammonium salt thereof, which contains at least one radioactive atom.
  • a compound can be labelled with positron or with gamma emitting radioactive isotopes.
  • the 3 H-atom or the 125 I-atom is the atom of choice to be replaced.
  • PET positron emitting
  • the most commonly used positron emitting (PET) radioactive isotopes are 11 C, 18 F, 15 O and 13 N, all of which are accelerator produced and have half-lives of 20, 100, 2 and 10 minutes respectively. Since the half-lives of these radioactive isotopes are so short, it is only feasible to use them at institutions which have an accelerator on site for their production, thus limiting their use.
  • the most widely used of these are 18 F, 99m Tc, 201 Tl and 123 I.
  • the handling of these radioactive isotopes, their production, isolation and incorporation in a molecule are known to the skilled person.
  • the radioactive atom is selected from the group of hydrogen, carbon, nitrogen, sulfur, oxygen, and halogen.
  • the radioactive atom is selected from the group of hydrogen, carbon, and halogen.
  • the radioactive isotope is selected from the group of 3 H, 11 C, 18 F, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br, and 82 Br.
  • the radioactive isotope is selected from the group of 3 H, 11 C, and 18 F.
  • a compound according to the invention can generally be prepared by a succession of steps, each of which is known to the skilled person.
  • a pyridinone derivative can be prepared according to one or more of the following preparation methods.
  • the copper coupling reaction is performed in the presence of a copper salt, such as Cu(OAC) 2 , in an aprotic solvent such as DCE, in the presence of an amine or amine N-oxide, such as pyridine or NMO, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 15 min at 180 °C under microwave irradiation.
  • a copper salt such as Cu(OAC) 2
  • an aprotic solvent such as DCE
  • an amine or amine N-oxide such as pyridine or NMO
  • the palladium coupling reaction is performed in an aprotic solvent such as toluene, in the presence of a palladium catalyst such as Pd(AcO) 2 , and in the presence of tBuOK, as a base, and a ligand, such as BINAP, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 24 hours at 100 °C under traditional heating.
  • aprotic solvent such as toluene
  • a palladium catalyst such as Pd(AcO) 2
  • tBuOK as a base
  • a ligand such as BINAP
  • A-R 3 is an amide
  • the coupling reaction is performed in an aprotic solvent such as dioxane or DMF, in the presence of CuI, N,N-dimethylethylendiamine and K 3 PO 4 as a base, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 20 minutes at 175 °C under microwave irradiation.
  • pyridinone derivative can be prepared according the procedure described in Scheme 1B.
  • the copper coupling reaction is performed in an aprotic solvent such as dioxane or DMF, in the presence of CuI, N,N-dimethylethylendiame as a ligand, and an inorganic base such as K 3 PO 4 , at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 20 minutes at 175 °C under microwave irradiation.
  • an aprotic solvent such as dioxane or DMF
  • CuI, N,N-dimethylethylendiame as a ligand
  • an inorganic base such as K 3 PO 4
  • the Hal-radical is a halogen, such as Br, or I.
  • XA can be OH, Br or I.
  • the copper coupling reaction is performed in an aprotic solvent such us dioxane or DMF, in the presence of CuI, N,N-dimethylethylenediamine as a ligand, and an inorganic base such as K 3 PO 4 , at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 20 minutes at 175 °C under microwave irradiation.
  • the OH-activation can be done via triflate, in the presence of trifluoromethanesulfonic anhydride or 1,1,1-trifluoro- N- phenyl- N- [(trifluoromethyl)sulfonyl]-methanesulfonamide, in an aprotic solvent such as DCM or THF, at a convenient temperature for completion of the reaction.
  • the palladium coupling reaction is performed in an aprotic solvent such as toluene or trifluorotoluene in the presence of a palladium catalyst such as Pd(AcO) 2 , and in the presence of a base, such as tBuOK, or Cs 2 CO 3 , and optionally a ligand, such as BINAP or xantphos is required, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 24 hours at 100 °C under traditional heating.
  • a palladium catalyst such as Pd(AcO) 2
  • a base such as tBuOK, or Cs 2 CO 3
  • a ligand such as BINAP or xantphos
  • the copper coupling reaction is performed in the presence of a copper salt, such as Cu(OAC) 2 , in an aprotic solvent such as DCE, in the presence of an amine or amine N-oxide, such as pyridine or NMO, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 15 min at 180 °C under microwave irradiation.
  • a copper salt such as Cu(OAC) 2
  • an aprotic solvent such as DCE
  • an amine or amine N-oxide such as pyridine or NMO
  • Halogenation is performed in the presence of phosphorus oxybromide or oxychloride, in an aprotic solvent such as DCE, at a convenient temperature to completion of the reaction, typically 150°C under microwave irradiation.
  • Alkylation is performed in the presence of an organic or inorganic base, such as NaH, or 1,8-diazabicyclo[5.4.0]undecene-7, in an aprotic solvent such as DME, CH 3 CN, or DMF at a convenient temperature to completion of the reaction, typically 120 °C for 10 minutes under microwave irradiation.
  • an organic or inorganic base such as NaH, or 1,8-diazabicyclo[5.4.0]undecene-7
  • an aprotic solvent such as DME, CH 3 CN, or DMF
  • Palladium coupling reaction is performed in an aprotic solvent such as toluene or dioxane in the presence of a palladium catalyst such as Pd(AcO) 2 , or Pd(PPh 3 ) 4 and in the presence of a base, such as tBuOK, or inorganic aqueous base such as Na 2 CO 3 , and sometimes a ligand, such as BINAP, is required, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 24 hours at 100 °C under traditional heating.
  • a palladium catalyst such as Pd(AcO) 2 , or Pd(PPh 3 ) 4
  • a base such as tBuOK
  • inorganic aqueous base such as Na 2 CO 3
  • a ligand such as BINAP
  • the copper coupling reaction is performed in the presence of a copper salt, such as Cu(OAc) 2 , in an aprotic solvent such as DCE, in the presence of an amine or amine N-oxide, such as pyridine or NMO, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 15 min at 180 °C under microwave irradiation.
  • a copper salt such as Cu(OAc) 2
  • an aprotic solvent such as DCE
  • an amine or amine N-oxide such as pyridine or NMO
  • the reduction reaction is performed in a protic solvent such as MeOH and in the presence of a reducing agent such as sodium borohydride, at room temperature and for a period of time to ensure the completion of the reaction, typically 30 min at room temperature.
  • a protic solvent such as MeOH
  • a reducing agent such as sodium borohydride
  • a Mitsunobu type reaction can be performed in the presence of a phosphine, such as triphenylphosphine, an azodicarboxylate derivative, such as diethylazodicarboxilate in an aprotic solvent, such as THF, at a convenient temperature and for a period of time to ensure the completion of the reaction, such as 100 °C for 5 minutes under microwave irradiation.
  • a phosphine such as triphenylphosphine
  • an azodicarboxylate derivative such as diethylazodicarboxilate
  • THF aprotic solvent
  • the palladium coupling reaction is performed in an aprotic solvent such as toluene, in the presence of a palladium catalyst such as Pd(AcO) 2 , and in the presence of tBuOK, as a base, and a ligand, such as BINAP, at a convenient temperature, either by conventional heating or under microwave irradiation, for a period of time to ensure the completion of the reaction, typically 24 hours at 100 °C under traditional heating.
  • aprotic solvent such as toluene
  • a palladium catalyst such as Pd(AcO) 2
  • tBuOK as a base
  • a ligand such as BINAP
  • a compound according to the invention in particular compounds according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, have surprisingly been shown to have a binding affinity towards the MCH-receptor, in particular towards the MCH-1 receptor, in particular as an antagonist.
  • a compound according to the invention are suitable for the prevention and/or treatment of diseases where antagonism of the MCH-receptor, in particular antagonism of the MCH-1 receptor is of therapeutic use.
  • a compound according to the invention may be suitable for treatment and/or prophylaxis of psychiatric disorders, including but not limited to :
  • a compound according to the invention may be used for treating sexual disorders, neurological disorders, and most in particular obesity and diabetes.
  • the invention therefore relates to a compound according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, for use as a medicine.
  • the invention also relates to the use of a compound according to the invention for the preparation of a medicament for the prevention and/or treatment of diseases where antagonism of the MCH-receptor, in particular antagonism of the MCH-1 receptor is of therapeutic use.
  • the invention also relates to the use of a compound according to the invention for the preparation of a medicament for the prevention and/or treatment of anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders. Additionally, a compound according to the invention may be used for treating sexual disorders and neurological disorders, and in particular obesity and diabetes.
  • a compound according to the invention, in particular according to Formula (I) may be co-administered as add-on treatment and/or prophylaxis in the above listed diseases.
  • a compound according to the invention in particular according to Formula (I) may be co-administered in combination with antidepressants, anxiolytics and/or antipsychotics which are currently available or in development or which will become available in the future, in particular to improve efficacy and/or onset of action.
  • a compound according to the present invention and one or more of the other agents may be present as a combined preparation for simultaneous, separate or sequential use for the prevention and/or treatment of depression and/or anxiety.
  • Such combined preparations may be, for example, in the form of a twin pack.
  • a compound of the present invention and one or more of the other agents may be administered as separate pharmaceutical compositions, either simultaneously or sequentially.
  • the invention therefore relates to a pharmaceutical composition according to the invention, characterized in that is comprises further one or more other compounds selected from the group of antidepressants, anxiolytics and antipsychotics.
  • Suitable classes of antidepressant agents include norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), corticotropin releasing factor (CRF) antagonists, ⁇ -adrenoreceptor antagonists and atypical antidepressants.
  • SSRIs selective serotonin reuptake inhibitors
  • MAOIs monoamine oxidase inhibitors
  • RIMAs reversible inhibitors of monoamine oxidase
  • SNRIs noradrenergic and specific serotonergic antidepressants
  • CRF corticotropin releasing factor
  • norepinephrine reuptake inhibitors include amitriptyline, clomipramine, doxepin, imipramine, trimipramine, amoxapine, desipramine, maprotiline, nortriptyline, protriptyline, reboxetine and pharmaceutically acceptable salts thereof.
  • Suitable examples of selective serotonin reuptake inhibitors include fluoxetine, fluvoxamine, paroxetine, sertraline and pharmaceutically acceptable salts thereof.
  • Suitable examples of monoamine oxidase inhibitors include isocarboxazid, phenelzine, tranylcypromine, selegiline and pharmaceutically acceptable salts thereof.
  • Suitable examples of reversible inhibitors of monoamine oxidase include moclobemide and pharmaceutically acceptable salts thereof.
  • Suitable examples of serotonin and noradrenaline reuptake inhibitors include venlafaxine and pharmaceutically acceptable salts thereof.
  • Suitable atypical antidepressants include bupropion, lithium, nefazodone, trazodone, viloxazine, sibutramine and pharmaceutically acceptable salts thereof.
  • antidepressants include adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, apelinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine, bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxe
  • Suitable classes of anti-anxiety agents include benzodiazepines and 5-HT 1A receptor agonists or antagonists, especially 5-HT 1A partial agonists, corticotropin releasing factor (CRF) antagonists, compounds having muscarinic cholinergic activity and compounds acting on ion channels.
  • benzodiazepines other suitable classes of anti-anxiety agents are nonbenzodiazepine sedative-hypnotic drugxs such as zolpidem; mood-stabilizing drugs such as clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol and vigabatrin; and barbiturates.
  • Suitable antipsychotic agents are selected from the group of acetophenazine, in particular the maleate salt; alentemol, in particular the hydrobromide salt; alpertine; azaperone; batelapine, in particular the maleate salt; benperidol; benzindopyrine, in particular the hydrochloride salt; brofoxine; bromperidol; butaclamol, in particular the hydrochloride salt; butaperazine; carphenazine, in particular the maleate salt; carvotroline, in particular the hydrochloride salt; chlorpromazine; chlorprothixene; cinperene; cintriamide; clomacran, in particular the phosphate salt; clopenthixol; clopimozide; clopipazan, in particular the mesylate salt; cloroperone, in particular the hydrochloride salt; clothiapine; clothixamide, in particular the maleate salt; clozapine; cycl
  • a compound according to the invention, in particular according to Formula (I) may also be used in conjunction with other lipid-lowering agent, thus leading to a so-called combination lipid-lowering therapy for the treatment of obesity.
  • the said additional lipid-lowering agent may be, for instance, a known drug conventionally used for the management of hyperlipidaemia such as e.g. a bile acid sequestrant resin, a fibric acid derivative or nicotinic acid as previously mentioned in the background of the invention.
  • Suitable additional lipid-lowering agents also include other cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors, especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors, HMG-CoA reductase gene expression inhibitors, CETP inhibitors, ACAT inhibitors, squalene synthetase inhibitors, CB-1 antagonists, cholesterol absorption inhibitors such as ezetimibe, and the like.
  • HMG-CoA reductase inhibitor refers to a compound which inhibits the biotransformation of hydroxymethylglutaryl-coenzyme A to mevalonic acid as catalyzed by the enzyme HMG-CoA reductase.
  • HMG-CoA reductase inhibitors are, for example, lovastatin, simvastatin, fluvastatin, pravastatin, rivastatin, and atorvastatin.
  • HMG-CoA synthase inhibitor refers to a compound which inhibits the biosynthesis of hydroxymethylglutaryl-coenzyme A from acetyl-coenzyme A and acetoacetyl-coenzyme A, catalyzed by the enzyme HMG-CoA synthase
  • HMG-CoA reductase gene expression inhibitor may be used as the second compound in the combination therapy aspect of this invention.
  • These agents may be HMG-CoA reductase trancription inhibitors that block the transcription of DNA or translation inhibitors that prevent translation of mRNA coding for HMG-CoA reductase into protein.
  • Such inhibitors may either affect trancription or translation directly or may be biotransformed into compounds having the above-mentioned attributes by one or more enzymes in the cholesterol biosynthetic cascade or may lead to accumulation of a metabolite having the above-mentioned activities.
  • CETP inhibitor refers to a compound which inhibits the cholesteryl ester transfer protein (CETP) mediated transport of various cholesteryl esters and triglycerides from HDL to LDL and VLDL.
  • CETP cholesteryl ester transfer protein
  • ACAT inhibitor refers to a compound which inhibits the intracellular esterification of dietary cholesterol by the enzyme acyl CoA:cholesterol acyltransferase.
  • squalene synthetase inhibitor refers to a compound which inhibits the condensation of two molecules of farnesylpyrophosphate to form squalene, catalyzed by the enzyme squalene synthetase.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a therapeutically effective amount of a compound according to the invention, in particular a compound according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof.
  • a compound according to the invention in particular a compound according to Formula (I), the pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof , or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes.
  • a compound according to Formula (I) the pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof , or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • compositions of this invention an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally, rectally, percutaneously, by parenteral injection or by inhalation.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof. Since the compounds according to the invention are potent orally administrable dopamine antagonists, pharmaceutical compositions comprising said compounds for administration orally are especially advantageous.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to the invention and one or more other compounds selected from the group of antidepressants, anxiolytics, antipsychotics and lipid-lowering agents as well as to the use of such a composition for the manufacture of a medicament.
  • THF means tetrahydrofuran
  • DMF means N,N-dimethylformamide
  • EtOAc means ethyl acetate
  • DCM means dichloromethane
  • DME means 1,2-dimethoxyethane
  • DCE means 1,2-dichloroethane
  • DIPE means diisopropylether
  • DMSO means dimethylsuffoxide
  • DIPEA means diisopropylethylamine
  • DIAD means diisopropyl diazodicarboxylate
  • TEMPO means 2,2,6,6-tetramethylpiperidin-1-oxyl Free Radical
  • BINAP means 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
  • TFA means trifluoroacetic acid
  • Xantphos means 4,5-bis(diphenylphosphino)
  • Microwave assisted reactions were performed in a single-mode reactor: Emrys TM Optimizer microwave reactor (Personal Chemistry A.B., currently Biotage) or Initiator TM Sixty (Biotage). Description of both instruments can be found in www.biotage.com. And in a multimode reactor: MicroSYNTH Labstation (Milestone, Inc.). Description of the instrument can be found in www.milestonesci.com.
  • Intermediate compound I-3 can also be obtained by adding trifluoromethanesulfonic anhydride (1.1 eq) at 0 °C to a mixture of intermediate compound I-2 , Et 3 N and DCM as the solvent. In this case the mixture is stirred for 2 hours at room temperature to complete reaction.
  • First compound 1-15 was converted to the free base (which corresponds to compound 1-13 ) by methods well known to a person skilled in the art. Then a reductive methyltion was performed overnight at 50 °C on a mixture of compound 1-13 (1.5 g, 0.0036 mol) and paraform (1 g) in methanol (150 ml), with Pt/C 5 % (0.5 g) as a catalyst in the presence of a thiophene solution (1.0 ml; 4 % in DIPE). Afer uptake of H 2 (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from CH 3 CN. The desired compound was filtered off. Yield: 1.2 g of compound 1-14 (78 %).
  • Tables 1 to 4 list the compounds of Formula (I), which are prepared according to one of the above described examples.
  • Table 1 Co. Nr. Scheme --L Salt forms 1-5 1A 1-12 1A .CF 3 COOH 1-8 1A 1-9 1A 1-11 1A 1-6 1A .CF 3 COOH 1-13 1A 1-15 1A .2HCl (and . 0.8H 2 O) 1-7 1A .CF 3 COOH 1-14 1A 1-10 1A 1-1 1A .HCl 1-2 1A 1-3 1A 1-4 1A .CF 3 COOH Table 2 Co. Nr. Scheme --R 3 --R 4 Salt forms 2-1 2 --H 2-2 2 --H 2-3 2 --H 2-4 2 --CH 3 Table 3 Co. Nr. Ex. Nr. -B-Y 1 -Y 2 -Y 3 -- Salt forms 3-1 3A 3-2 3A 3-3 3B 3-4 3A Table 4 Co. Nr. Scheme -L Salt forms 4-1 1B
  • the HPLC measurement was performed using a HP 1100 from Agilent Technologies comprising a pump (quaternary or binary) with degasser, an autosampler, a column oven, a diode-array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with an electrospray ionization source. Nitrogen was used as the nebulizer gas. The source temperature was maintained at 140 °C. Data acquisition was performed with MassLynx-Openlynx software.
  • the HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C, unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second.
  • the capillary needle voltage was 3 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas.
  • Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • the LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55 °C), a diode-array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds.
  • the capillary needle voltage was 3.5 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas.
  • Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • Reversed phase HPLC was carried out on an ACE-C18 column (3.0 ⁇ m, 4.6 x 30 mm) from Advanced Chromatography Technologies, with a flow rate of 1.5 ml/min, at 40 °C.
  • the gradient conditions used are: 80 % A (0.5 g/l ammonium acetate solution), 10 % B (acetonitrile), 10 % C (methanol) to 50 % B and 50 % C in 6.5 minutes, to 100 % B at 7 minutes and equilibrated to initial conditions at 7.5 minutes until 9.0 minutes. Injection volume 5 ⁇ l.
  • High-resolution mass spectra (Time of Flight, TOF) were acquired only in positive ionization mode by scanning from 100 to 750 in 0.5 seconds using a dwell time of 0.1 seconds.
  • the capillary needle voltage was 2.5 kV for positive ionization mode and the cone voltage was 20 V.
  • Leucine-Enkephaline was the standard substance used for the lock mass calibration.
  • Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 ⁇ m, 4.6 x 100 mm) with a flow rate of 1.6 ml/min.
  • Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 6.5 minutes, to 1 % A and 99 % B in 1 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes.
  • An injection volume of 10 ⁇ l was used.
  • Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • Reversed phase UPLC Ultra Performance Liquid Chromatography
  • BEH bridged ethylsiloxane/silica hybrid
  • Waters Acquity a flow rate of 0.8 ml/min.
  • Two mobile phases (mobile phase A: 0.1 % formic acid in H 2 O/methanol 95/5; mobile phase B: methanol) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 minutes and hold for 0.2 minutes.
  • An injection volume of 0.5 ⁇ l was used.
  • Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30 °C/minute. Maximum temperature was 400 °C. Values are peak values.
  • melting points were determined with a DSC822e (Mettler-Toledo). Melting points were measured with a temperature gradient of 10 °C/minute. Final temperature was set at 300 °C. Values are peak values.
  • melting points were determined in open capillary tubes on a Mettler FP62 apparatus. Melting points were measured with a temperature gradient of 10 °C/minute. Maximum temperature was 300 °C. The melting point was read from a digital display.
  • MCH-1 receptors The interaction of the compounds of Formula (I) with MCH-1 receptors was assessed in in vitro transient calcium (Ca 2+ ) mobilization assays in the fluorimetric imaging plate reader (FLIPR) format ( Sullivan et al. 1999, Methods Mol Biol 114:125-133 ).
  • the natural agonist (MCH) is incubated with cells expressing the MCH-1 receptor, which elicits a concentration-dependent transient mobilization of Ca 2+ from internal stores.
  • the interaction of the test compounds with the receptor is assessed in competition experiments. Various concentrations of the test compound are added to the incubation mixture containing the receptor-expressing cells and a submaximal concentration of MCH.
  • the test compound in proportion to its antagonist potency and its concentration inhibits MCH-induced Ca 2+ mobilization.
  • CHO Chinese Hamster ovary cells stably expressing the human MCH-1 receptor are grown in a 1:1 mixture of Dulbecco's Modified Eagles Medium (DMEM) and HAM's F12 medium including Glutamax TM (Invitrogen), supplemented with 10 % heat-inactivated fetal bovine serum and 400 ⁇ g/ml geneticin.
  • DMEM Dulbecco's Modified Eagles Medium
  • Glutamax TM Invitrogen
  • MCH-1 receptor-expressing CHO cells are seeded in 20 ⁇ l (5,000 cells per well) into 384-well black wall, clear bottom microtiter plates (Costar).
  • 20 ⁇ l per well calcium assay kit containing 10 mM probenicide (Molecular Devices) is added. Cells are loaded for 90 min at 37 °C and 5 % CO 2 in a cell culture incubator. After loading, 20 ⁇ l of serial dilutions of the test compound are added and cells are further incubated for 20 min at room temperature in the dark. After 20 min, 20 ⁇ l of a submaximal MCH concentration is added and changes in intracellular calcium are recorded directly in a FLIPR III apparatus (Molecular devices).
  • All compounds according to Formula (I) produced an inhibition of more than 50 % (pIC 50 ) at a test concentration ranging between 10 -6 M and 10 -9 M in a concentration-dependent manner.
  • Example C.2 Determination of hERG-reduction
  • HERG human ether-à-go-go -related gene encodes a potassium channel with biophysical properties similar to the rapidly activating delayed-rectifier K + current (I Kr ) in cardiac myocytes ( Snyders, D.J. & Chaudhary, A. (1996). High affinity open channel block by dofetilide of HERG expressed in a human cell line. Molecular Pharmacology 49, 949-955 and Smith, P.L., Baukrowitz, T. & Yellen, G. (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379, 833-836 ).
  • This I Kr current contributes to the K + current responsible for the repolarization phase of the cardiac action potential. Blocking this current may prolong action potential duration and cause long QT-syndrome.
  • QT prolongation can lead to the occurrence of ventricular arrhythmias such as Torsades de Pointes which can result in sudden death.
  • HERG human embryonic kidney cell line
  • HEK293 human embryonic kidney cell line with a stable transfection of HERG was used ( Mohammad, S., Zhou, Z., Gong, Q. & January, C.T. (1997).
  • the bath solution contained 137 mM NaCl, 4 mM KCl, 10 mM glucose, 10 mM HEPES, 1.8 mM CaCl 2 and 1 mM MgCl 2 (pH 7.4 with NaOH).
  • the pipette solution contained 130 mM KCl, 5 mM EGTA, 10 mM HEPES, 5 mM MgATP and 1 mM MgCl 2 (pH 7.2 with KOH).
  • Test compounds were dissolved in DMSO to obtain a stock solution of 10-2 M to 3 x 10-1 M (final DMSO concentration : 0.3, 0.1 or 0.03 %).
  • the PatchXpress system was primed with bath and pipette solution.
  • a 16-well sealchip (Sealchip16, Aviva Biosciences Corp.) was loaded into the system and primed before preparing cells in the bath solution suspension.
  • the eppendorf tube filled with cells was placed into the designated position and the procedure commenced with the trituration and dispersion of cells into each recording chamber (well) of the sealchip.
  • the PatchXpress system followed the general principles of conventional whole-cell patch-clamping.
  • the HERG current was determined as the maximal tail current at -50 mV after a 4.8 second depolarization to +20 mV, starting from a holding potential of - 80 mV. Each value represents the average current from 4 sequential voltage pulses. To determine the extent of block the residual current was compared with vehicle pretreatment. The effect of the test compound on the HERG current was measured after 5 minutes of drug application. If more than 5 % reduction of the HERG current can be observed, the test substance is considered to (partially) block the HERG current.
  • Control experiments Time-matched vehicle control experiments were performed under identical conditions. Astemizole was used as a reference compound known to inhibit the HERG-mediated current at nanomolar concentrations. Table 7 : Comparison of hERG-reduction values. Compound Structure hERG-reduction (%) at 3 ⁇ M Prior art compound (Banyu 2005/085200) 38.9 % Prior art compound (Banyu 2005/085200) 42.6% Compound 1-7 -1.8 % Compound 1-12 0.7 % Compound 2-1 15.6 %
  • Active ingredient (a.i.) as used throughout these examples relates to a final compound of formula (i), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N -oxide form thereof, a quaternary ammonium salt thereof and prodrugs thereof.
  • Example D.1 oral drops
  • 500 Grams of the a.i. is dissolved in 0.5 1 of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60 ⁇ 80 °c. After cooling to 30 ⁇ 40 °C there are added 35 l of polyethylene glycol and the mixture is stirred well. Then there is added a solution of 1750 grams of sodium saccharin in 2.5 l of purified water and while stirring there are added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg/ml of a.i. The resulting solution is filled into suitable containers.
  • Example D.2 oral solution
  • Example D.3 film-coated tablets
  • a mixture of 100 grams of the a.i., 570 grams lactose and 200 grams starch is mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 ml of water.
  • the wet powder mixture is sieved, dried and sieved again.
  • 100 grams microcrystalline cellulose and 15 grams hydrogenated vegetable oil is added. The whole is mixed well and compressed into tablets, giving 10,000 tablets, each containing 10 mg of the active ingredient.
  • Example D.4 injectable solution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (33)

  1. Verbindung gemäß Formel (I)
    Figure imgb0107
     ein pharmazeutisch unbedenkliches Säure- oder Basenadditionssalz davon, eine N-Oxidform davon oder ein quartäres Ammoniumsalz davon, wobei:
    A für einen Rest gemäß Formel (II) steht
    Figure imgb0108
     wobei
    k, l, m, n jeweils unabhängig voneinander für eine ganze Zahl gleich 0, 1, 2, 3 oder 4 stehen, mit der Maßgabe, dass (k+l) und (m+n) gleich 2, 3, 4 oder 5 ist; wobei eine der -CH2-Gruppierungen durch O ersetzt sein kann; und wobei die -CH2-Gruppierungen jeweils durch Oxo substituiert sein können;
    X für CH oder N steht;
    R3 aus der Gruppe Wasserstoff, C1-5-Alkyl, C36-Cycloalkyl und C1-5-Alkyloxycarbonyl ausgewählt ist;
    R4, R5 jeweils unabhängig voneinander aus der Gruppe Wasserstoff, Halogen, Cyano, Hydroxy, Amino, Oxo, Carboxyl, Nitro, Thio, Formyl, C1-3-Alkyl und C1-3-Alkyloxy ausgewählt sind;
    p für eine ganze Zahl gleich null, 1, 2 oder 3 steht;
    q für eine ganze Zahl gleich null, 1, 2 oder 3 steht;
    Y1, Y3 jeweils unabhängig voneinander aus der Gruppe Einfachbindung, O, NR7, S, SO und SO2 ausgewählt sind; wobei R7 aus der Gruppe Wasserstoff und C1-3-Alkyl ausgewählt ist;
    Y2 für einen gesättigten oder ungesättigten, geradkettigen oder verzweigten C1-6-Kohlenwasserstoffrest steht, wobei ein oder mehrere Wasserstoffatome gegebenenfalls durch einen Rest ausgewählt aus der Gruppe Halogen, Cyano, Hydroxy, Amino, Oxo, Carboxyl, Nitro, Thio und Formyl ersetzt sein können;
    B für einen 6-gliedrigen Ring mit null, 1, 2 oder 3 Stickstoffatomen steht, der gegebenenfalls durch r Substituenten R6 substituiert ist, die jeweils unabhängig voneinander aus der Gruppe Halogen, Cyano, Hydroxy, Amino, Oxo, Carboxyl, Nitro, Thio, Formyl, C1-3-Alkyl und C1-3-Alkyloxy ausgewählt sind; und wobei r für eine ganze Zahl gleich 1 oder 2 steht; oder zwei Substituenten R6 zu einem Rest - CH2CH2CH2- oder -OCH2O- kombiniert sein können;
    Alkyl für einen geradkettigen oder verzweigten gesättigten Kohlenwasserstoffrest mit der angegebenen Anzahl an Kohlenstoffatomen steht; wobei der Rest gegebenenfalls an einem oder mehreren Kohlenstoffatomen durch einen oder mehrere Reste ausgewählt aus der Gruppe Halogen, Cyano, Hydroxy, Amino, Oxo, Carboxyl, Nitro, Thio und Formyl substituiert sein kann; und
    Halogen für Fluor, Chlor, Brom oder Iod steht.
  2. Verbindung nach Anspruch 1, dadurch gekennzeichnet, dass k, l, m, n jeweils unabhängig voneinander für eine ganze Zahl gleich 1, 2 oder 3 stehen, mit der Maßgabe, dass (k+l) und (m+n) gleich 2, 3 oder 4 ist.
  3. Verbindung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass A aus der Gruppe (a-1), (b-1), (b-3), (b-5) und (c-2) ausgewählt ist.
    Figure imgb0109
    Figure imgb0110
  4. Verbindung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass A für einen Rest gemäß Formel (cc-2) steht.
    Figure imgb0111
  5. Verbindung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass A für einen Rest gemäß (aa-1) oder (bb-1) steht.
    Figure imgb0112
  6. Verbindung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass R3 aus der Gruppe Wasserstoff, C3-6-Cycloalkyl und C1-5-Alkyl ausgewählt ist.
  7. Verbindung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass X für Kohlenstoff-H oder Stickstoff steht.
  8. Verbindung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass R4 und R5 jeweils unabhängig voneinander aus der Gruppe Wasserstoff, Halogen, C1-3-Alkyl und C1-3-Alkyloxy ausgewählt sind.
  9. Verbindung nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass p für null oder 1 steht.
  10. Verbindung nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, dass q für null steht.
  11. Verbindung nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, dass Y1 und Y3 jeweils unabhängig voneinander aus der Gruppe Einfachbindung und O ausgewählt sind.
  12. Verbindung nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, dass Y2 aus der Gruppe -CH2-, -CH2CH2- und -CH=CH- ausgewählt ist.
  13. Verbindung nach einem der Ansprüche 1 bis 12, dadurch gekennzeichnet, dass B für Phenyl steht.
  14. Verbindung nach Anspruch 13, dadurch gekennzeichnet, dass B durch einen Halogensubstituenten substituiert ist.
  15. Verbindung nach einem der Ansprüche 1 bis 13, dadurch gekennzeichnet, dass die Gruppierung B-Y1-Y2-Y3 aus den Resten (a1-2), (a1-3) und (a1-5), gegebenenfalls substituiert durch r Substituenten R6, ausgewählt ist.
    Figure imgb0113
  16. Verbindung nach Anspruch 1, ein pharmazeutisch unbedenkliches Säure- oder Basenadditionssalz davon, eine N-Oxidform davon oder ein quartäres Ammoniumsalz davon, wobei:
    k, l, m, n jeweils unabhängig voneinander für eine ganze Zahl gleich 1, 2 oder 3 stehen, mit der Maßgabe, dass (k+l) und (m+n) gleich 2, 3 oder 4 ist; wobei eine der -CH2-Gruppierungen durch O ersetzt sein kann; und wobei die - CH2-Gruppierungen jeweils durch Oxo substituiert sein können;
    X für CH oder N steht;
    R3 aus der Gruppe Wasserstoff, C3-6-Cycloalkyl und C1-5-Alkyl ausgewählt ist;
    R4, R5 jeweils unabhängig voneinander aus der Gruppe Wasserstoff, Halogen, C1-3-Alkyl und C1-3-Alkyloxy ausgewählt sind;
    p für eine ganze Zahl gleich null oder 1 steht;
    q für eine ganze Zahl gleich null steht;
    Y1, Y3 jeweils unabhängig voneinander aus der Gruppe Einfachbindung und O ausgewählt sind;
    Y2 für einen gesättigten oder ungesättigten, geradkettigen oder verzweigten C1-6-Kohlenwasserstoffrest steht; und
    B für Phenyl, gegebenenfalls substituiert durch einen Halogensubstituenten R6, steht.
  17. Verbindung nach Anspruch 1, pharmazeutisch unbedenkliches Säure- oder Basenadditionssalz davon, N-Oxidform davon oder quartäres Ammoniumsalz davon, wobei:
    A aus der Gruppe (a-1), (b-1), (b-3), (b-5) und (c-2) ausgewählt ist,
    Figure imgb0114
    Figure imgb0115
    X für CH oder N steht;
    R3 aus der Gruppe Wasserstoff, C3-6-Cycloalkyl und C1-5-Alkyl ausgewählt ist;
    R4, R5 jeweils unabhängig voneinander aus der Gruppe Wasserstoff, Halogen, C1-3-Alkyl und C1-3-Alkyloxy ausgewählt sind;
    p für eine ganze Zahl gleich null oder 1 steht;
    q für eine ganze Zahl gleich null steht; die Gruppierung B-Y1-Y2-Y3 aus den Resten (a1-2), (a1-3) und (a1-5), gegebenenfalls substituiert durch r Substituenten R6, ausgewählt ist,
    Figure imgb0116
    R6 für einen Halogensubstituenten steht; und wobei
    r für eine ganze Zahl gleich 1 oder 2 steht.
  18. Verbindung nach Anspruch 1, pharmazeutisch unbedenkliches Säure- oder Basenadditionssalz davon, N-Oxidform davon oder quartäres Ammoniumsalz davon, wobei:
    A aus der Gruppe (a-1), (b-1), (b-3), (b-5) und (c-2) ausgewählt ist,
    Figure imgb0117
    Figure imgb0118
    X für CH oder N steht;
    R3 aus der Gruppe Wasserstoff, C3-5-Cycloalkyl und C1-3-Alkyl ausgewählt ist;
    R4, R5 jeweils unabhängig voneinander aus der Gruppe Wasserstoff, Halogen, C1-3-Alkyl und C1-3-Alkyloxy ausgewählt sind;
    p für eine ganze Zahl gleich null oder 1 steht;
    q für eine ganze Zahl gleich null steht;
    Y1, Y3 jeweils unabhängig voneinander aus der Gruppe Einfachbindung und O ausgewählt sind;
    Y2 für einen gesättigten oder ungesättigten, geradkettigen oder verzweigten C1-6-Kohlenwasserstoffrest steht; und
    B für Phenyl, gegebenenfalls substituiert durch einen Halogensubstituenten R6, steht.
  19. Verbindung nach Anspruch 1, pharmazeutisch unbedenkliches Säure- oder Basenadditionssalz davon, N-Oxidform davon oder quartäres Ammoniumsalz davon, wobei:
    A aus der Gruppe (a-1) und (b-1) ausgewählt ist;
    Figure imgb0119
    X für CH steht;
    R3 für Methyl steht;
    R4, R5 jeweils unabhängig voneinander aus der Gruppe Wasserstoff und Halogen ausgewählt sind;
    p für eine ganze Zahl gleich null oder 1 steht;
    q für eine ganze Zahl gleich null steht;
    Y1 für eine Einfachbindung steht;
    Y3 für O steht;
    Y2 für CH2 steht; und
    B für Phenyl steht.
  20. Verbindung nach einem der Ansprüche 1 bis 19 zur Verwendung als Medizin.
  21. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutisch unbedenklichen Träger oder ein pharmazeutisch unbedenkliches Verdünnungsmittel und, als Wirkstoff, eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 19.
  22. Pharmazeutische Zusammensetzung nach Anspruch 21, dadurch gekennzeichnet, dass sie in einer für die orale Verabreichung geeigneten Form vorliegt.
  23. Pharmazeutische Zusammensetzung nach Anspruch 21 oder 22, dadurch gekennzeichnet, dass sie weiterhin eine oder mehrere andere Verbindungen, ausgewählt aus der Gruppe der Antidepressiva, Anxiolytika und Antipsychotika, umfasst.
  24. Pharmazeutische Zusammensetzung nach einem der Ansprüche 21 bis 23, dadurch gekennzeichnet, dass sie weiterhin eine oder mehrere andere Verbindungen, ausgewählt aus der Gruppe der lipidsenkenden Verbindungen, umfasst.
  25. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung nach einem der Ansprüche 21 bis 24, dadurch gekennzeichnet, dass man einen pharmazeutisch unbedenklichen Träger innig mit einer therapeutisch wirksamen Menge einer Verbindung nach einem der Ansprüche 1 bis 19 mischt.
  26. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung nach Anspruch 23, dadurch gekennzeichnet, dass man einen pharmazeutisch unbedenklichen Träger innig mit einer therapeutisch wirksamen Menge einer Verbindung nach einem der Ansprüche 1 bis 19 und einer oder mehreren anderen Verbindungen, ausgewählt aus der Gruppe der Antidepressiva, Anxiolytika und Antipsychotika, mischt.
  27. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung nach Anspruch 24, dadurch gekennzeichnet, dass man einen pharmazeutisch unbedenklichen Träger innig mit einer therapeutisch wirksamen Menge einer Verbindung nach einem der Ansprüche 1 bis 19 und einer oder mehreren anderen Verbindungen, ausgewählt aus der Gruppe der lipidsenkenden Verbindungen, mischt.
  28. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 19 zur Herstellung eines Medikaments zur Prävention und/oder Behandlung von Krankheiten, bei denen ein Antagonismus des MCH-Rezeptors, insbesondere ein Antagonismus des MCH-1-Rezeptors, von therapeutischem Nutzen ist.
  29. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 19 zur Herstellung eines Medikaments zur Prävention und/oder Behandlung von psychiatrischen Erkrankungen, einschließlich, jedoch nicht darauf beschränkt, Angst, Essstörungen, Stimmungsstörungen wie bipolaren Störungen und Depression, Psychosen wie Schizophrenie, und Schlafstörungen; Obesitas; Diabetes; sexuellen Störungen und neurologischen Störungen.
  30. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 19 in Kombination mit einer oder mehreren Verbindungen, ausgewählt aus der Gruppe der Antidepressiva, Anxiolytika und Antipsychotika zur Herstellung eines Medikaments zur Prävention und/oder Behandlung von Angst, Essstörungen, Stimmungsstörungen wie bipolaren Störungen und Depression, Psychosen wie Schizophrenie und Schlafstörungen.
  31. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 19 in Kombination mit einer oder mehreren anderen Verbindungen ausgewählt aus der Gruppe der lipidsenkenden Verbindungen zur Herstellung eines Medikaments zur Prävention und/oder Behandlung von Obesitas.
  32. Verbindung nach einem der Ansprüche 1 bis 19 zur Verwendung bei der Prävention und/oder Behandlung von Krankheiten, bei denen ein Antagonismus des MCH-Rezeptors, insbesondere ein Antagonismus des MCH-1-Rezeptors von therapeutischem Nutzen ist.
  33. Verbindung nach einem der Ansprüche 1 bis 19 zur Verwendung bei der Prävention und/oder Behandlung von psychiatrischen Erkrankungen einschließlich, jedoch nicht darauf beschränkt, Angst, Essstörungen, Stimmungsstörungen wie bipolaren Störungen und Depression, Psychosen wie Schizophrenie, und Schlafstörungen, Obesitas; Diabetes; sexuellen Störungen und neurologischen Störungen.
EP07847809.6A 2006-12-05 2007-12-04 Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen Active EP2102208B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07847809.6A EP2102208B1 (de) 2006-12-05 2007-12-04 Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125421 2006-12-05
EP07847809.6A EP2102208B1 (de) 2006-12-05 2007-12-04 Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen
PCT/EP2007/063310 WO2008068265A1 (en) 2006-12-05 2007-12-04 Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases

Publications (2)

Publication Number Publication Date
EP2102208A1 EP2102208A1 (de) 2009-09-23
EP2102208B1 true EP2102208B1 (de) 2014-04-23

Family

ID=37963935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07847809.6A Active EP2102208B1 (de) 2006-12-05 2007-12-04 Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen

Country Status (11)

Country Link
US (1) US8158643B2 (de)
EP (1) EP2102208B1 (de)
JP (1) JP5290192B2 (de)
CN (1) CN101541796B (de)
AU (1) AU2007328979B2 (de)
CA (1) CA2664112C (de)
ES (1) ES2483866T3 (de)
IL (1) IL199075A (de)
MX (1) MX2009005908A (de)
RU (1) RU2461558C2 (de)
WO (1) WO2008068265A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007430A (es) * 2008-01-11 2010-12-21 Albany Molecular Res Inc Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana.
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
WO2010147234A1 (en) * 2009-06-18 2010-12-23 Banyu Pharmaceutical Co.,Ltd. Diarylamide-spirodiamine derivative
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (de) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinon-substituiertes azepin[b]indol und pyrido-pyrrolo-azepin mch-1 antagonisten, verfahren zur herstellung und verwendung davon
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
PE20130781A1 (es) 2010-07-06 2013-07-20 Astrazeneca Ab Agentes terapeuticos 976
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
UY34194A (es) * 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
EP2875001B1 (de) 2012-07-18 2019-01-09 Sunshine Lake Pharma Co., Ltd. Heterocyclische stickstoffderivate und deren anwendung in arzneimitteln
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
AU2016304408B2 (en) 2015-07-31 2019-02-21 Pfizer Inc., 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
CN116082225A (zh) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN107698498A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
BR112019014688A2 (pt) 2017-01-20 2020-02-18 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
MX2019008690A (es) 2017-01-23 2019-09-18 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
EP4076527A4 (de) * 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. Therapeutische wirkstoffkombinationen und verfahren zu ihrer verwendung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
DE10233817A1 (de) 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2542220A1 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
DE102004003812A1 (de) 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004003811A1 (de) 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1741703A4 (de) * 2004-03-05 2009-11-25 Banyu Pharma Co Ltd Pyridonderivat
US20050256124A1 (en) 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2664112A1 (en) 2008-06-12
JP2010511666A (ja) 2010-04-15
AU2007328979A1 (en) 2008-06-12
US20100035909A1 (en) 2010-02-11
US8158643B2 (en) 2012-04-17
AU2007328979B2 (en) 2013-05-09
RU2009125578A (ru) 2011-01-20
EP2102208A1 (de) 2009-09-23
CA2664112C (en) 2015-02-17
CN101541796A (zh) 2009-09-23
IL199075A (en) 2014-09-30
MX2009005908A (es) 2009-06-16
JP5290192B2 (ja) 2013-09-18
ES2483866T3 (es) 2014-08-08
WO2008068265A1 (en) 2008-06-12
CN101541796B (zh) 2012-11-07
RU2461558C2 (ru) 2012-09-20

Similar Documents

Publication Publication Date Title
EP2102208B1 (de) Neuartige substituierte diazaspiropyridinon-derivate zur verwendung bei mch-1-vermittelten erkrankungen
WO2007141200A1 (en) Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases
WO2007071646A1 (en) Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
US20100029620A1 (en) Substituted triazoline, tetrazolone and imidazolone derivatives for use as a medicine
EP2091942B1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
US20090281099A1 (en) Substituted pyrazinone derivatives for use as a medicine
EP2013202B1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
EP1966191B1 (de) Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20111125

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131129

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 663789

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007036285

Country of ref document: DE

Effective date: 20140605

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2483866

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140808

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 663789

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140423

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140723

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140724

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140823

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140825

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007036285

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150126

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007036285

Country of ref document: DE

Effective date: 20150126

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141204

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140423

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20071204

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20211110

Year of fee payment: 15

Ref country code: FR

Payment date: 20211109

Year of fee payment: 15

Ref country code: IE

Payment date: 20211109

Year of fee payment: 15

Ref country code: NL

Payment date: 20211116

Year of fee payment: 15

Ref country code: GB

Payment date: 20211028

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20211110

Year of fee payment: 15

Ref country code: CH

Payment date: 20211116

Year of fee payment: 15

Ref country code: BE

Payment date: 20211119

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20220104

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20220622

Year of fee payment: 16

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221204

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221205

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221204

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221204

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007036285

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240702